期刊文献+

肉瘤样肾细胞癌合并腔静脉癌栓1例报告并文献复习

下载PDF
导出
摘要 肉瘤样肾细胞癌临床少见,具有恶性程度高、进展快、预后差的临床特点。肉瘤合并腔静脉癌栓形成者临床上更为罕见,我院泌尿外科近期收治1例肉瘤样肾细胞癌合并腔静脉癌栓患者,现结合相关文献复习报道如下。患者,女,50岁,因"体检发现右肾占位3d"入院。无腰腹痛及血尿,无其他慢性病史及肝炎结核病史。查体:右肾区叩击痛阴性,双下肢无水肿。
出处 《现代泌尿生殖肿瘤杂志》 2014年第5期309-310,共2页 Journal of Contemporary Urologic and Reproductive Oncology
  • 相关文献

参考文献10

  • 1Roohi M, Tanvir I, Qazi S. Sarcomatoid renal cell carcinoma [J]. Int J Pathol,2012,10(1):39-40.
  • 2Shuch B, Bratslavsky G, IAnehan WM, et al. Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatmentstrategies[J]. Oncologist, 2012,17 ( 1 ) : 46-54.
  • 3Bellmunt J, Dutcher J. Targeted therapies and the treatment of non-clear cell renal cell carcinoma[J]. Ann Oncol, 2013,24(7):1730-1740.
  • 4Reiter M, Schwope R, Clarkson A, et al. Sarcomatoid renal cell carcinoma: a case report and literature review[J]. J Radi- ol Case Rep,2012,6(4), 11-16.
  • 5Haas NB, Lin X, Manola J, et al. A phase II trial of doxoru bicin and gemeitabine in renal cell carcinoma with sarcomatoid features: ECOG8802[J]. Med 0ncol,2012,29(2) :761 -767.
  • 6Roubaud G, Gross Goupil M, Wallerand H, et al. Combina- tion of gemcitabine and doxorubiein in rapidly progressive me tastatic renal cell earcinomaand/or sarcomatoid renal cell car cinoma[J]. Oncology,2011,80(3-4) :214-218.
  • 7张海梁,叶定伟,姚旭东,张世林,载波,沈益君,朱耀,朱一平,施国海,马春光,肖文军,秦晓健,林国文.索拉非尼治疗具有肉瘤样分化的转移性肾癌的疗效观察[J].中华泌尿外科杂志,2010,31(1):15-17. 被引量:5
  • 8Cost NG, Delacroix SE Jr, Sleeper JP, et al. The impact of targeted molecular therapies on the level of renal cell carcino- ma vena caval tumorthrombus[J]. Ear Urol, 2011,59(6): 912-918.
  • 9Yazici S, Inci K, Bilen CY, etal. Renal cell carcinoma with inferior vena cava thrombus: the Hacettepe experience [ J]. Urol Oncol, 2010,28 (6) : 603-609.
  • 10Bertini R, Roscigno M, Freschi M, et al. Impact of venous tumour thrombus consistency (solid vs friable) on cancer-spe- cific survival in patientswith renal cell carcinoma[J]. Eur U rology, 2011,60(2) : 358-365.

二级参考文献8

  • 1Golshayan AR, George S, Heng DY, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol, 2009, 277:235-241.
  • 2Delahunt B. Sarcomatoid renal carcinoma: the final common dedifferentiation pathway of renal epithelial malignancies. Pathology, 1999, 31: 185-190.
  • 3Sella A, Logothetis CJ, Ro JY, et al. Sarcomatoid renal cell carcinoma: a treatable entity. Cancer, 1987, 60: 1313-1318.
  • 4Mian BM, Bhadkamkar N, Slaton JW, et at. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol, 2002, 167: 65-70.
  • 5de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol, 2001, 25: 275-284.
  • 6Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma response to interleukin-2 based therapy. J Immunother, 2005, 28: 488-495.
  • 7Oda H, Nakatsuru Y, Ishikawa T. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res, 1995, 55: 658-662.
  • 8Staehler M, SchOppler G, Haseke N, et al. Sorafenib is superior to combination therapy with gemcitabine plus doxorubicin for patients with sarcomatoid renal cell carcinoma[C/OL]. Alexandria: American Society of Clinical Oncotogy, 2008 [2009-8-121. www. asco. org/ASCOv2/Meetings/Abstracts? &vmvlew=abst detail view&. conf ID=54& abstract ID= 20498.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部